Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.
Hosted on MSN54m
After Less than Two Years as CEO, Unilever's Hein Schumacher Receives His Walking PapersIn a development that's startled analysts and serves as a reminder that shorter tenures apply to CEOs and CMOs alike, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback